Evidence for an interaction between α-MSH and opioids in the regulation of gonadotropin secretion in man
| Autor: | P. Ajmone-Catt, P Calvelli, T. Lima, G. M. Molinatti, F. Altare, Paolo Piero Limone |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Peptide hormone Pharmacology Placebo Gonadotropin-Releasing Hormone Endocrinology Bolus (medicine) Internal medicine medicine Humans Drug Interactions Testosterone Infusions Intravenous Opioid peptide Endogenous opioid Naloxone business.industry Antagonist Luteinizing Hormone Gonadotropin secretion alpha-MSH Injections Intravenous Follicle Stimulating Hormone Gonadotropin business Gonadotropins hormones hormone substitutes and hormone antagonists |
| Zdroj: | Journal of Endocrinological Investigation. 20:207-210 |
| ISSN: | 1720-8386 0391-4097 |
| DOI: | 10.1007/bf03346904 |
| Popis: | Gonadotropin secretion is inhibited by the endogenous opioids and stimulated by their antagonist naloxone. LH secretion is stimulated by alpha-MSH, a tridecapeptide derived from the post-translational processing of POMC. The possibility that alpha-MSH interacts with the opioids, as suggested by the experimental evidence, was investigated in 7 normal males aged 24-29 through the performance of seven tests: naloxone (0.8 mg i.v. bolus, followed by infusion of 1.6 mg/h for 120'); alpha-MSH (2.5 mg i.v. bolus); naloxone + alpha-MSH (2.5 mg i.v. 15' after commencement of the naloxone infusion); naloxone + GnRH (100 micrograms i.v. 15' after commencement of the naloxone infusion); alpha-MSH + GnRH (respectively 2.5 mg and 100 micrograms at time 0), GnRH alone (100 micrograms at time 0), placebo (150 nmol/l NaCl solution). The LH AUCs during both naloxone (30.3 +/- 2.7 mIU/ml.min-1) and alpha-MSH test (32.9 +/- 4.6 mIU/ml.min-1) were significantly greater (p0.005) than that observed during placebo (16.9 +/- 3.6 mIU/ml.min-1). The LH AUC during alpha-MSH + naloxone (37.6 +/- 2.6 mIU/ml.min-1) was not significantly different from that recorded during their separate administration. GnRH injected alone, during the naloxone infusion and with alpha-MSH produced similar increases in LH, that were significantly higher than that observed during the other tests (AUCs: GnRH 89.4 +/- 10.6, GnRH + naloxone 100.5 +/- 9.1, GnRH + alpha-MSH 94.6 +/- 7.9 mIU/ml.min-1, p0.001). Significant increase in FSH (p0.001) was only observed during GnRH, GnRH + naloxone and GnRH + aMSH tests (AUCs: placebo 13.3 +/- 1.7; naloxone 14.7 +/- 2.5; alpha-MSH 15.5 +/- 2.3; alpha-MSH + naloxone 16.9 +/- 1.9; GnRH 19.1 +/- 1.1; GnRH + alpha-MSH 20.7 +/- 1.3; GnRH + naloxone 21.2 +/- 1.8 mIU/ml.min-1). These results are in line with the possibility of an interaction between alpha-MSH and the opioids in the regulation of gonadotropin secretion, perhaps with opposing effects on a final common pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink